Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 7/20 | 0.38 |
| ▸ | SPR | P35270 | 3/20 | 0.36 |
| ▸ | F12 | P00748 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21183596 | 0.96 | C5AR1 (0.41) | C5AR1F12HPGDSPARP1TNKS2 | |
| SCHEMBL31692488 | 0.92 | C5AR1 (0.39) | C5AR1SPRF12TP53HPGDS | |
| SCHEMBL30178446 | 0.87 | C5AR1 (0.42) | C5AR1F12TP53HPGDSPARP1 | |
| SCHEMBL20015372 | 0.87 | C5AR1 (0.42) | C5AR1F12TP53HPGDSPARP1 | |
| SCHEMBL20014993 | 0.87 | C5AR1 (0.41) | C5AR1SPRF12TP53HPGDS | |
| SCHEMBL20015363 | 0.86 | C5AR1 (0.41) | C5AR1F12HPGDSPARP1TNKS2 | |
| SCHEMBL20015359 | 0.85 | LMNA (0.36) | — | |
| SCHEMBL21175426 | 0.83 | GLP1R (0.35) | — | |
| SCHEMBL31692385 | 0.83 | GLP1R (0.34) | — | |
| SCHEMBL31692418 | 0.82 | F12 (0.45) | C5AR1SPRF12TP53HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304572-A1 | HETEROCYCLIC GLP-1R AGONISTS | BIOMEA FUSION, INC. | 2025-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304572-A1 | HETEROCYCLIC GLP-1R AGONISTS | GLP1R, GPR119, GIPR | C5AR1 1540/4885SPR 4064/4885F12 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.